CytomX Therapeutics Inc（CTMX）財務資料CTMXCytomX Therapeutics Inc

Evaluating the bottom line, CytomX Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1677.08%, while the net margin is -1457.40%. These profitability ratios, combined with a Return on Equity (ROE) of -39.18%, provide a clear picture of how effectively CTMX converts its operational activities into shareholder value.

In the context of the broader market, CTMX competes directly with industry leaders such as DBVT and PBYI. With a market capitalization of $546.93M, it holds a significant position in the sector. When comparing efficiency, CTMX's gross margin of 100.00% stands against DBVT's 100.00% and PBYI's 77.92%. Such benchmarking helps identify whether CytomX Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

CytomX has reported a significant revenue decline of 92.4% year-over-year, with Q2 2026 revenue at only $1.42 million, far below expectations. The company has also posted continuous net losses, with a net income of -$20.67 million in Q2 2026, reflecting ongoing financial struggles.